Akoya Biosciences, Inc. (AKYA)

Market Cap	107.06M
Revenue (ttm)	86.82M
Net Income (ttm)	-57.97M
Shares Out	49.56M
EPS (ttm)	-1.17
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	116,967
Open	2.160
Previous Close	2.160
Day's Range	2.080 - 2.290
52-Week Range	1.880 - 6.310
Beta	1.35
Analysts	Buy
Price Target	4.40 (+103.7%)
Earnings Date	Nov 14, 2024

About AKYA

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microar...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Apr 16, 2021
• Employees: 330
• Stock Exchange: NASDAQ
• Ticker Symbol: AKYA
• Website: https://www.akoyabio.com

Financial Performance

In 2023, Akoya Biosciences's revenue was $96.63 million, an increase of 29.09% compared to the previous year's $74.86 million. Losses were -$63.32 million, -10.36% less than in 2022.

Analyst Forecast

According to 8 analysts, the average rating for AKYA stock is "Buy." The 12-month stock price forecast is $4.4, which is an increase of 103.70% from the latest price.

Price Target

$4.4

(103.70% upside)

Analyst Consensus: Buy